StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Non-GAAP SG&A adjustments by Quarter

Non-GAAP SG&A adjustments ($M) ($M)

QuarterlyAnnual

Gilead Sciences Non-GAAP SG&A adjustments: $400M in Q2 2026, up 5,614.3% from a year earlier. That is the highest of the 36 quarters on record here.

Latest, Q2 2026
400
Period ended Jun 30, 2026
Change on a year earlier
+5,614.3%
7 in Q2 2025
History
36 quarters
Since Q4 2016
Sources
30
Documents cited below

Where the Q2 2026 figure comes from

“|| Selling, general and administrative expenses adjustments | 400 | 7 | 488 | 43”

Source: Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗

Reported in Form 8-K GAAP to Non-GAAP Reconciliation.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNon-GAAP SG&A adjustments ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026400+5,614.3%Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 202688+144.4%Form 8-K (exhibit991earningspressrel.htm, filed 2026-05-07) ↗
Q4 2025Dec 31, 2025106+96.3%Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
Q3 2025Sep 30, 20255-82.1%Form 8-K (exhibit991earningspressrel.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 20257-73.1%Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 202536-55.0%Form 8-K (exhibit991earningspressrel.htm, filed 2026-05-07) ↗
Q4 2024Dec 31, 202454+390.9%Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
Q3 2024Sep 30, 202428+64.7%Form 8-K (exhibit991earningspressrel.htm, filed 2025-10-30) ↗
Q2 2024Jun 30, 202426+2,500.0%Form 8-K (exhibit991earningspressrel.htm, filed 2025-08-07) ↗
Q1 2024Mar 31, 202480+7,900.0%Form 8-K (exhibit991earningspressrel.htm, filed 2025-04-24) ↗
Q4 2023Dec 31, 202311-63.3%Form 8-K (exhibit991earningspressrel.htm, filed 2025-02-11) ↗
Q3 2023Sep 30, 202317+1,600.0%Form 8-K (exhibit991earningspressrel.htm, filed 2024-11-06) ↗
Q2 2023Jun 30, 20231-98.8%Form 8-K (exhibit991earningspressrel.htm, filed 2024-08-08) ↗
Q1 2023Mar 31, 20231–Form 8-K (exhibit991earningspressrel.htm, filed 2024-04-25) ↗
Q4 2022Dec 31, 202230-65.1%Form 8-K (exhibit991earningspressrel.htm, filed 2024-02-06) ↗
Q3 2022Sep 30, 20221-91.7%Form 8-K (exhibit991earningspressrel.htm, filed 2023-11-07) ↗

Cite this data

StockData. (2026). Gilead Sciences Non-GAAP SG&A adjustments ($M), quarterly Q4 2016–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/ng-adj-sga

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.